ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,341 to 3,360 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
QIV-HD vs QIV-SD: Number of Participants Reporting Serious Adverse Events (SAEs)2 of 1,049

5 of 1,051

-0.3 points

-0.9 to 0.3

2,100NCT04498832

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

QIV-HD vs QIV-SD: serious adverse events2 of 1,049

5 of 1,051

-0.3 points

-0.9 to 0.3

2,100NCT04498832

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

13vPnC: Visit 1 to Visit 2 vs 13vPnC: 6-month Follow-up: serious adverse events10 of 1,049

41 of 1,049

-3.0 points

-4.4 to -1.7

2,098NCT00500266

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

Standard Supportive Care (SOC) vs Epoetin Alfa: serious adverse events229 of 1,045

251 of 1,051

-2.0 points

-5.6 to 1.6

2,096NCT00338286

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Uric Acid124 of 1,514

48 of 579

-0.1 points

-2.9 to 2.4

2,093NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Albumin3 of 1,514

1 of 579

0.0 points

-0.8 to 0.4

2,093NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Triglycerides329 of 1,514

101 of 579

4.3 points

0.4 to 7.9

2,093NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Glucose7 of 1,514

1 of 579

0.3 points

-0.5 to 0.8

2,093NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Cholesterol1 of 1,514

1 of 579

-0.1 points

-0.9 to 0.2

2,093NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Amylase92 of 1,514

35 of 579

0.0 points

-2.5 to 2.2

2,093NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Alkaline Phosphatase (AP)7 of 1,514

0 of 579

0.5 points

-0.2 to 1.0

2,093NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Bilirubin6 of 1,514

3 of 579

-0.1 points

-1.1 to 0.5

2,093NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Creatinine52 of 1,514

18 of 579

0.3 points

-1.6 to 1.9

2,093NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Creatinine Kinase49 of 1,514

6 of 579

2.2 points

0.8 to 3.4

2,093NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: γ-Glutamyl-transferase (GGT)54 of 1,514

14 of 579

1.1 points

-0.6 to 2.6

2,093NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Haematology: Red Blood Cell Count31 of 1,513

13 of 579

-0.2 points

-1.9 to 1.1

2,092NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Haematology: Haematocrit48 of 1,513

22 of 579

-0.6 points

-2.7 to 1.0

2,092NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Abnormalities in Haematology: Haemoglobin63 of 1,513

31 of 579

-1.2 points

-3.5 to 0.7

2,092NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

OsmoPrep Tablets vs HalfLytely and Bisacodyl Tablet: serious adverse events20 of 1,041

19 of 1,051

0.1 points

-1.1 to 1.3

2,092NCT01427296

Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing

Old Lina vs New Lina: Number of Patients With Abnormalities in Haematology: Eosinophils91 of 1,512

33 of 579

0.3 points

-2.1 to 2.4

2,091NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=168"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=168

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04498832-7114cff6",
        "title": "QIV-HD vs QIV-SD: Number of Participants Reporting Serious Adverse Events (SAEs)",
        "summary": "2 of 1049 against 5 of 1051; risk difference -0.3 points, 95% interval -0.9 to 0.3; NCT04498832, Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older",
        "record": "/library/comparisons/NCT04498832-7114cff6",
        "nct_id": "NCT04498832",
        "kind": "outcome",
        "participants": 2100,
        "risk_difference": {
          "value": -0.0028507962365498744,
          "lower": -0.009330958749956448,
          "upper": 0.0028589972677190755
        },
        "group_1": "2 of 1,049",
        "group_2": "5 of 1,051",
        "difference": "-0.3 points",
        "interval": "-0.9 to 0.3",
        "trial_title": "Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older"
      },
      {
        "id": "NCT04498832-sae",
        "title": "QIV-HD vs QIV-SD: serious adverse events",
        "summary": "2 of 1049 against 5 of 1051; risk difference -0.3 points, 95% interval -0.9 to 0.3; NCT04498832, Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older",
        "record": "/library/comparisons/NCT04498832-sae",
        "nct_id": "NCT04498832",
        "kind": "serious-adverse-events",
        "participants": 2100,
        "risk_difference": {
          "value": -0.0028507962365498744,
          "lower": -0.009330958749956448,
          "upper": 0.0028589972677190755
        },
        "group_1": "2 of 1,049",
        "group_2": "5 of 1,051",
        "difference": "-0.3 points",
        "interval": "-0.9 to 0.3",
        "trial_title": "Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=169",
  "request_id": "X5i_ljvz83xTPff8"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?